US biotech to submit new psoriasis treatment to the FDA in summer

Dermavant Sciences has presented an interim analysis of phase III results from trial involving new treatment for plaque psoriasis, which will form basis for FDA new drug application.

In 2022, US skin doctors may get their hands on a new tool for treating patients with plaque psoriasis.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading